Benitec Biopharma (BNTC) Stock Overview
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BNTC Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Benitec Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.65 |
| 52 Week High | US$17.15 |
| 52 Week Low | US$9.70 |
| Beta | 0.29 |
| 1 Month Change | -4.04% |
| 3 Month Change | -11.41% |
| 1 Year Change | 14.22% |
| 3 Year Change | 198.73% |
| 5 Year Change | -86.74% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Jan 31Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth
Oct 16
Companies Like Benitec Biopharma (NASDAQ:BNTC) Can Afford To Invest In Growth
May 29Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition
Jan 20Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth
Oct 02Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable
Nov 30Benitec Biopharma prices of $18M securities offering
Sep 13Benitec GAAP EPS of -$2.23, revenue of $0.07M
Sep 02We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate
Jan 13We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully
Sep 30Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?
May 12Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?
Jan 27How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?
Dec 02Shareholder Returns
| BNTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | 0.8% | 1.0% |
| 1Y | 14.2% | 29.7% | 14.0% |
Return vs Industry: BNTC underperformed the US Biotechs industry which returned 29.7% over the past year.
Return vs Market: BNTC matched the US Market which returned 14% over the past year.
Price Volatility
| BNTC volatility | |
|---|---|
| BNTC Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BNTC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BNTC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 19 | Jerel Banks | benitec.com |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Benitec Biopharma Inc. Fundamentals Summary
| BNTC fundamental statistics | |
|---|---|
| Market cap | US$400.78m |
| Earnings (TTM) | -US$41.82m |
| Revenue (TTM) | n/a |
Is BNTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.82m |
| Earnings | -US$41.82m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BNTC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 23:13 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Benitec Biopharma Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |